The newsroom includes access to CHA News, which provides timely information to members every Thursday and is at the core of CHA benefits. In addition, it is also home to resources such as toolkits and talking points designed to help member hospitals and health systems communicate with internal and external audiences on a range of current health care-related issues. Links to CHA media statements and press releases can also be found here.
Newsroom
President Trump Signs Executive Order to Lower Prescription Drug Prices
This post has been archived and contains information that may be out of date.
Earlier this week, President Trump issued a new executive order on lowering drug prices. It directs the U.S. Health and Human Services Secretary to immediately take steps to conduct rulemaking on a model that would test limiting Medicare payments for Part B drugs to no more than a “most-favored-nation” price.
Governor Signs COVID-19-Specific Workers’ Compensation Presumption Law
This post has been archived and contains information that may be out of date.
Today, Gov. Newsom signed Senate Bill 1159, adopting a COVID-19-specific presumption in the workers’ compensation system for employees who test positive for COVID-19. The new law takes effect immediately.
CHA’s 2020 Consent Manual Now Available and Ready for Free Download
This post has been archived and contains information that may be out of date.
CHA is pleased to release the 2020 Consent Manual, which features updates and insights on current consent and related health care law. The manual is available free to members for download and in the CHA Manuals app. Printed copies may be purchased here.
Updates for the Week of Sept. 14
This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services issued the following update this week:
Alternative Payment Model (APM) Incentive Payment Advisory for Clinicians – Request for Current Billing Information for Qualifying APM Participants
CEO Message: Good News on Proposed Federal Medi-Cal Cuts
This post has been archived and contains information that may be out of date.
On Monday, the Centers for Medicare & Medicaid Services (CMS) announced its intent to withdraw a proposal that would have cut total Medicaid funding by as much as $49 billion annually (8% of the program).
CMS Withdraws Medicaid Fiscal Accountability Rule
This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma announced on Twitter on Monday that the agency has withdrawn its proposed Medicaid Fiscal Accountability Rule.
DMHC Issues All Plan Letter on Telehealth During COVID-19 Pandemic
This post has been archived and contains information that may be out of date.
On Sept. 4, the Department of Managed Health Care issued All Plan Letter (APL) 20-032 as a continuation of its policies on telehealth during the COVID-19 state of emergency.
35 California Representatives Sign Letter to HHS Secretary on 340B Drug Program Violations
This post has been archived and contains information that may be out of date.
Last week, 246 members of the House of Representatives, including 35 from California, signed a letter to Health and Human Services Secretary Azar urging him to use his authority to address recent actions taken by pharmaceutical companies that undermine the 340B Drug Pricing Program.
Results of SAMHSA’s 2019 National Survey on Drug Use and Health Now Available
This post has been archived and contains information that may be out of date.
Last week, the Substance Abuse and Mental Health Services Administration released the 2019 National Survey on Drug Use and Health. The annual survey is the nation’s primary resource for data on mental health and substance use among Americans.
Urge Representatives to Sign ‘Dear Colleague’ Letter on 340B Drugs
This post has been archived and contains information that may be out of date.
Hospitals participating in the 340B program are being urged to ask their representatives to sign an important Dear Colleague letter to the Department of Health and Human Services (HHS), in response to recent actions taken by several drug companies to limit the distribution of certain 340B drugs to hospitals and health systems.
